Status:
COMPLETED
Voriconazole as Prophylaxis for Liver Transplant Recipients
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Pfizer
Conditions:
Fungemia
Mycoses
Eligibility:
All Genders
18+ years
Brief Summary
The study aims to determine if voriconazole prevents invasive fungal infections in liver transplant recipients. Endpoints would be: occurrence of invasive fungal infection and fungal colonization. Two...
Detailed Description
The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, voriconazole usage prophylactically, physical exam findings, laboratory a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients receiving a liver transplant at University of Pittsburgh Medical Center (UPMC) between January 1, 2001 and June 30, 2005.
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00177788
Start Date
September 1 2005
End Date
August 1 2012
Last Update
August 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213